Category: Research

The biennial CRUK Brain Tumour Conference returned to London for 2024.

Researchers in Newcastle have found a key genetic variation in medulloblastomas that may pave the way for more effective targeted treatments.

Mum of three Emma, 41, from Lowestoft, made several medical appointments before she was diagnosed with multiple meningiomas in 2022.

We’re proud to announce the latest recipients of our Future Leaders grants that’ve been awarded for their innovative new research projects.

Our Junior Fellow Dr Spencer Watson and his team at The Ludwig Institute for Cancer Research at the University of Lausanne in Switzerland are researching new ways to treat glioblastoma.

This month we sponsored an event in Manchester which brought together brain tumour experts to talk about new technologies that could improve brain tumour care.

The National Institute for Health and Care Research (NIHR) has announced two new calls for research into brain tumours.

With our funding, researchers in Canada have found key features in different meningiomas that can help predict tumour response to the most common treatments.

Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma.

An international phase 3 clinical trial has shown that vorasidenib could be a new targeted treatment for those diagnosed with a low-grade glioma.

As Artificial Intelligence (AI) becomes more common in our day-to-day life, what does this mean for the future of research into brain tumours?

We are pleased to announce that we have awarded £3 million to two new, exciting research projects!

Innovative imaging technology and machine learning developed by our Future Leader, Dr Spencer Watson, helps us understand how glioblastomas respond to treatment.

One of our first Junior Fellowship grant holders, Dr Tyler Miller, has opened his own research lab focused on developing immunotherapies to treat brain tumours.

The guidelines recently published by NICE mean that NHS England will be using dabrafenib and trametinib – the first ever targeted treatment for childhood brain tumours – to treat children whose tumours have a BRAF V600E mutation.

Recently, we were given the exciting opportunity to visit a research laboratory at Oxford University, headed by Professor Daniel Ebner, where they are using state-of-the-art robots to help in the fight against glioblastoma.

The Ways Ahead project aims to find ways to support, and improve quality of life for those diagnosed with a lower-grade brain tumour. It also explores ways to help friends and family who are supporting those diagnosed.

We are pleased to announce the two researchers who have been awarded our latest Expanding Theories grant!

What happened to the £40m of Government funding that was committed to research into brain tumours in 2018?

Research that we funded nearly 20 years ago laid the foundations for last week’s approval of dabrafenib and trametinib to treat childhood gliomas.

CAR-T cell therapy is a type of immunotherapy that may be promising for treating brain tumours. There is lots of research in this field across the globe and it may one day be used more widely to treat this devastating disease.

The Brain Tumour Charity are delighted to announce a new partnership with two Family Led Charities that share the same aims of improving outcomes for children diagnosed with high grade brain tumours

Peter Buckle is a patient advocate and has worked with several teams, including the ARISTOCRAT team to champion research and clinical trials.

Living with a lower-grade glioma has a profound impact on those diagnosed, and their families. This is well documented anecdotally but needs to be scientifically addressed so that everyone affected by a brain tumour diagnosis gets the help and support they need.